PharmaBiome AG

PharmaBiome AG is a Swiss-based startup that is pioneering the development of microbiome-based therapies using proprietary tools for their design and production. Founded in 2015 as a spin-off from ETH Zurich, the company has created a first-in-the-industry, patent-protected technology platform for the production of standardized microbiome-based products. Situated at the intersection of microbiology, biotechnology, and data science, PharmaBiome is focused on developing the biotechnology necessary to produce solutions compliant with the safety, efficacy, and trial requirements of human medicine. The company has invested significant time in developing a biology-based analysis tool that allows for the identification and selection of the metabolic functions essential to restore the gut microbiome to a balanced state. PharmaBiome has been recognized with several startup awards, including Venture Kick, the ETH Spark Award, and the BaseLaunch Accelerator. Its most recent investment was a Fr.1.75M Convertible Note investment on 08 July 2020. PharmaBiome's innovative approach holds promise in creating personalized treatments for patients with chronic inflammatory diseases, immune conditions, and special nutritional needs. The flexibility and speed of their production process provide a unique advantage in creating effective treatment options. With its focus on addressing disturbances of the gut microbiome, PharmaBiome AG stands at the forefront of advancing microbiome-based therapies.